Review article: Emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 11, 2016, Pages 1109-1123

  Noureddin, M ^a   Anstee, Q M ^b   Loomba, R ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ARAMCHOL; CENICRIVIROC; ELAFIBRANOR; EMRICASAN; FARNESOID X RECEPTOR; GR MD 02; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; LIVER PROTECTIVE AGENT; LIVER X RECEPTOR; NUCLEAR RECEPTOR NR1D1; OBETICHOLIC ACID; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PLACEBO; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SELONSERTIB; SIMTUZUMAB; SONIC HEDGEHOG PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

BARIATRIC SURGERY; CALORIC RESTRICTION; CLINICAL TRIAL (TOPIC); COFFEE; COMBINATION DRUG THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EXERCISE; EXTRACELLULAR MATRIX; HEPATITIS; HUMAN; HYPERINSULINEMIA; INNATE IMMUNITY; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FIBROSIS; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84963739666     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13620     Document Type: Review

References (136)

1. Younossi ZM, Stepanova M, Afendy M, et al,. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-30 e1; quiz e60.
2. Cohen JC, Horton JD, Hobbs HH,. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-23.
3. Singh S, Allen AM, Wang Z, et al,. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-54 e9.
4. McPherson S, Hardy T, Henderson E, et al,. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62: 1148-55.
5. Angulo P, Kleiner DE, Dam-Larsen S, et al,. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-97 e10.
6. Ekstedt M, Hagstrom H, Nasr P, et al,. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-54.
7. Romeo S, Kozlitina J, Xing C, et al,. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
8. Valenti L, Al-Serri A, Daly AK, et al,. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
9. Kozlitina J, Smagris E, Stender S, et al,. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-6.
10. Liu YL, Reeves HL, Burt AD, et al,. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014; 5: 4309.
11. Quigley EM, Monsour HP,. The gut microbiota and nonalcoholic fatty liver disease. Semin Liver Dis 2015; 35: 262-9.
12. Bian Z, Ma X,. Liver fibrogenesis in non-alcoholic steatohepatitis. Front Physiol 2012; 3: 248.
13. Porepa L, Ray JG, Sanchez-Romeu P, et al,. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010; 182: E526-31.
14. Campbell PT, Newton CC, Patel AV, et al,. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012; 35: 1835-44.
15. Wong VW, Wong GL, Choi PC, et al,. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74.
16. Marra F, Bertolani C,. Adipokines in liver diseases. Hepatology 2009; 50: 957-69.
17. Brun P, Castagliuolo I, Pinzani M, et al,. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2005; 289: G571-8.
18. Seki E, De Minicis S, Osterreicher CH, et al,. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
19. Watanabe A, Hashmi A, Gomes DA, et al,. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007; 46: 1509-18.
20. Miura K, Kodama Y, Inokuchi S, et al,. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139: 323-34. e7.
21. Ishikawa S, Ikejima K, Yamagata H, et al,. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol 2011; 54: 1195-204.
22. Syn WK, Oo YH, Pereira TA, et al,. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010; 51: 1998-2007.
23. Williams CD, Stengel J, Asike MI, et al,. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
24. Review Team, LaBrecque DR, Abbas Z, et al,. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 2014; 48: 467-73.
25. Friedman SL,. Pathogenesis of hepatic fibrosis. In: UpToDate, Post TW, (Ed), UpToDate, Waltham, MA. (Accessed on March 23, 2016).
26. Rojkind M, Giambrone MA, Biempica L,. Collagen types in normal and cirrhotic liver. Gastroenterology 1979; 76: 710-9.
27. Gressner AM,. The cell biology of liver fibrogenesis-an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998; 292: 447-52.
28. Marra F, Aleffi S, Bertolani C, et al,. Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 44-7.
29. Friedman SL,. Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH. Nat Rev Gastroenterol Hepatol 2013; 10: 71-2.
30. Henao-Mejia J, Elinav E, Jin C, et al,. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-85.
31. Miura K, Yang L, van Rooijen N, et al,. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 2013; 57: 577-89.
32. Guy CD, Suzuki A, Zdanowicz M, et al,. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 2012; 55: 1711-21.
33. Nobili V, Carpino G, Alisi A, et al,. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology 2012; 56: 2142-53.
34. Lee YA, Wallace MC, Friedman SL,. Pathobiology of liver fibrosis: a translational success story. Gut 2015; 64: 830-41.
35. Koek GH, Liedorp PR, Bast A,. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-305.
36. McCarty MF,. Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease. Med Hypotheses 2011; 77: 550-6.
37. Sanyal AJ, Chalasani N, Kowdley KV, et al,. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
38. Sanyal AJ, Mofrad PS, Contos MJ, et al,. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
39. Serviddio G, Bellanti F, Vendemiale G,. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med 2013; 65: 952-68.
40. Al-Serri A, Anstee QM, Valenti L, et al,. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 2012; 56: 448-54.
41. Bugianesi E, Manzini P, D'Antico S, et al,. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-87.
42. Arsov T, Larter CZ, Nolan CJ, et al,. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006; 342: 1152-9.
43. Chen A, Tang Y, Davis V, et al,. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology 2013; 57: 2202-12.
44. Larter CZ, Yeh MM, Van Rooyen DM, et al,. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658-68.
45. Teratani T, Tomita K, Suzuki T, et al,. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012; 142: 152-64. e10.
46. Tomita K, Teratani T, Suzuki T, et al,. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014; 59: 154-69.
47. Tomita K, Teratani T, Suzuki T, et al,. Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J Hepatol 2014; 61: 98-106.
48. Van Rooyen DM, Gan LT, Yeh MM, et al,. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013; 59: 144-52.
49. Van Rooyen DM, Larter CZ, Haigh WG, et al,. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-403, 1403 e1-5.
50. Henle T,. Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids 2005; 29: 313-22.
51. Jiang JX, Chen X, Fukada H, et al,. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-alpha-converting enzyme activity in mice. Hepatology 2013; 58: 1339-48.
52. Leung C, Herath CB, Jia Z, et al,. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol 2014; 60: 832-8.
53. Miura K, Seki E, Ohnishi H, et al,. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010; 2010: 362847.
54. Seki E, Brenner DA,. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-35.
55. Rivera CA, Adegboyega P, van Rooijen N, et al,. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-9.
56. Tajiri K, Shimizu Y, Tsuneyama K, et al,. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009; 21: 673-80.
57. Adler M, Taylor S, Okebugwu K, et al,. Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. World J Gastroenterol 2011; 17: 1725-31.
58. Chang TT, Liaw YF, Wu SS, et al,. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
59. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
60. Marcellin P, Gane E, Buti M, et al,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
61. D'Ambrosio R, Aghemo A, Rumi MG, et al,. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-43.
62. Ng V, Saab S,. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 923-30.
63. Singh S, Khera R, Allen AM, et al,. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015; 62: 1417-32.
64. Boettcher E, Csako G, Pucino F, et al,. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35: 66-75.
65. Friedman SL,. Emerging therapies for hepatic fibrosis: uptodate.com, 2014.
66. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
67. Spengler EK, Loomba R,. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc 2015; 90: 1233-46.
68. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al,. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367-78 e5; quiz e14-5.
69. Lee S, Bacha F, Hannon T, et al,. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes 2012; 61: 2787-95.
70. Marchesini G, Petta S, Dalle Grave R,. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology 2015; Dec 11. doi: 10.1002/hep.28392. [Epub ahead of print].
71. Hocking MP, Duerson MC, O'Leary JP, et al,. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. N Engl J Med 1983; 308: 995-9.
72. Lassailly G, Caiazzo R, Buob D, et al,. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149: 379-88.
73. Mudaliar S, Henry RR, Sanyal AJ, et al,. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-82 e1.
74. Ali AH, Carey EJ, Lindor KD,. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 2015; 3: 5.
75. Pellicciari R, Costantino G, Camaioni E, et al,. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem 2004; 47: 4559-69.
76. Fuchs M,. Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012; 2012: 934396.
77. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al,. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-65.
78. Fang S, Suh JM, Reilly SM, et al,. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21: 159-65.
79. Aoyama T, Paik YH, Watanabe S, et al,. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 2012; 56: 2316-27.
80. Paik YH, Iwaisako K, Seki E, et al,. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 2011; 53: 1730-41.
81. Cui W, Matsuno K, Iwata K, et al,. NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology 2011; 54: 949-58.
82. Doherty GM, Jensen JC, Alexander HR, et al,. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110: 192-8.
83. Duman DG, Ozdemir F, Birben E, et al,. Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2007; 52: 2520-4.
84. Van Wagner LB, Koppe SW, Brunt EM, et al,. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10: 277-86.
85. Xue X, Piao JH, Nakajima A, et al,. Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem 2005; 280: 33917-25.
86. Ozawa K, Miyazaki M, Matsuhisa M, et al,. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes 2005; 54: 657-63.
87. Ozcan U, Cao Q, Yilmaz E, et al,. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61.
88. Ozcan U, Yilmaz E, Ozcan L, et al,. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-40.
89. Puri P, Mirshahi F, Cheung O, et al,. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 568-76.
90. Zein CO, Lopez R, Fu X, et al,. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012; 56: 1291-9.
91. Zein CO, Yerian LM, Gogate P, et al,. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-9.
92. Singh S, Khera R, Allen AM, et al,. Comparative effectiveness of pharmacological interventions for non-alcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015; 62: 1417-32.
93. Yang RY, Rabinovich GA, Liu FT,. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10: e17.
94. Di Lella S, Sundblad V, Cerliani JP, et al,. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 2011; 50: 7842-57.
95. Henderson NC, Sethi T,. The regulation of inflammation by galectin-3. Immunol Rev 2009; 230: 160-71.
96. Traber PG, Zomer E,. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS ONE 2013; 8: e83481.
97. Traber PG, Chou H, Zomer E, et al,. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS ONE 2013; 8: e75361.
98. Seki E, de Minicis S, Inokuchi S, et al,. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009; 50: 185-97.
99. Lefebvre E, Hashiguchi T, Jenkins H, et al,. Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH. Hepatology 2013; 58: 221A-2A.
100. Hong F, Chou H, Friedman SL,. Significant anti-fibrotic a'activity of cenicriviroc, a dual CCR2/CCR5 antagonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis. Hepatology 2013; 58: 1381A-2A.
101. Serbinova EA, Packer L,. Antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Methods Enzymol 1994; 234: 354-66.
102. Kagan VE,. Tocopherol stabilizes membrane against phospholipase A, free fatty acids, and lysophospholipids. Ann N Y Acad Sci 1989; 570: 121-35.
103. Blokhina O, Virolainen E, Fagerstedt KV,. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot 2003; 91: 179-94.
104. Brigelius-Flohe R,. Vitamin E: the shrew waiting to be tamed. Free Radic Biol Med 2009; 46: 543-54.
105. Fang F, Kang Z, Wong C,. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. Mol Nutr Food Res 2010; 54: 345-52.
106. Lavine JE, Schwimmer JB, Van Natta ML, et al,. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-68.
107. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al,. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
108. Klein EA, Thompson IM Jr, Tangen CM, et al,. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
109. Belfort R, Harrison SA, Brown K, et al,. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
110. Bakuradze T, Boehm N, Janzowski C, et al,. Antioxidant-rich coffee reduces DNA damage, elevates glutathione status and contributes to weight control: results from an intervention study. Mol Nutr Food Res 2011; 55: 793-7.
111. Misik M, Hoelzl C, Wagner KH, et al,. Impact of paper filtered coffee on oxidative DNA-damage: results of a clinical trial. Mutat Res 2010; 692: 42-8.
112. Kempf K, Herder C, Erlund I, et al,. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 2010; 91: 950-7.
113. Loftfield E, Shiels MS, Graubard BI, et al,. Associations of coffee drinking with systemic immune and inflammatory markers. Cancer Epidemiol Biomarkers Prev 2015; 24: 1052-60.
114. Modi AA, Feld JJ, Park Y, et al,. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51: 201-9.
115. Molloy JW, Calcagno CJ, Williams CD, et al,. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55: 429-36.
116. Anty R, Marjoux S, Iannelli A, et al,. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012; 57: 1090-6.
117. Bambha K, Wilson LA, Unalp A, et al,. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2014; 34: 1250-8.
118. Miele L, Valenza V, La Torre G, et al,. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-87.
119. Anand G, Zarrinpar A, Loomba R,. Targeting dysbiosis for the treatment of liver disease. Semin Liver Dis 2016; 36: 37-47.
120. Iacono A, Raso GM, Canani RB, et al,. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011; 22: 699-711.
121. Aller R, De Luis DA, Izaola O, et al,. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090-5.
122. Malaguarnera M, Vacante M, Antic T, et al,. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-53.
123. Eslamparast T, Poustchi H, Zamani F, et al,. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014; 99: 535-42.
124. Anstee QM, Concas D, Kudo H, et al,. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 2010; 53: 542-50.
125. Witek RP, Stone WC, Karaca FG, et al,. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009; 50: 1421-30.
126. Ratziu V, Sheikh MY, Sanyal AJ, et al,. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55: 419-28.
127. Shiffman M, Freilich B, Vuppalanchi R, et al,. A placebo-controlled, multicenter, double-blind, randomised trial of emricasan (IDN-6556) in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases. In: International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL), Vienna, Austria, April 22-26, 2015.
128. Staels B, Rubenstrunk A, Noel B, et al,. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013; 58: 1941-52.
129. Ratziu V, Harrison SA, Francque SM, et al,. An international, phase 2 randomized controlled trial of the dual PPAR α-δ agonist GFT505 in adult patients with NASH. Hepatology 2015; 62: 261A-5A.
130. Safadi R, Konikoff FM, Mahamid M, et al,. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 2085-91 e1.
131. Karnik S, Charlton MR, Li L, et al,. Efficacy of an ASK1 inhibitor to reduce fibrosis and steatosis in a murine model of NASH is associated with normalization of lipids and hepatic gene expression and a reduction in serum biomarkers of inflammation and fibrosis. In: The Liver Meeting 2015, San Francisco, CA, November 13-17, American Association for the Study of Liver Diseases, 2015.
132. Karnik S, Charlton M, Popov Y, et al,. Pharmacological inhibition of apoptosis signal-regulating kinase 1 (ASK1) in a murine model of NASH with pre-existing disease blocks fibrosis, steatosis, and insulin resistance. In: The Liver Meeting 2014, Boston, Massachusetts, November 7-11, American Association for the Study of Liver Diseases, 2014.
133. Hirsova P, Ibrahim SH, Bronk SF, et al,. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS ONE 2013; 8: e70599.
134. Moon HJ, Finney J, Ronnebaum T, et al,. Human lysyl oxidase-like 2. Bioorg Chem 2014; 57: 231-41.
135. Barry-Hamilton V, Spangler R, Marshall D, et al,. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-17.
136. Torok NJ, Dranoff JA, Schuppan D, et al,. Strategies and endpoints of antifibrotic drug trials: summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015; 62: 627-34.